Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, August 16, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Vamil Divan Initiated (VERA) at Strong Buy and Held Target at $27 on, Aug 16th, 2023
Vamil Divan of Guggenheim, Initiated "Vera Therapeutics, Inc." (VERA) at Strong Buy and Held Target at $27 on, Aug 16th, 2023.
Vamil has made no other calls on VERA in the last 4 months.
There are 2 other peers that have a rating on VERA. Out of the 2 peers that are also analyzing VERA, 1 agrees with Vamil's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Laura Chico of "Wedbush" Maintained at Hold with Increased Target to $16 on, Friday, August 11th, 2023
This is the rating of the analyst that currently disagrees with Vamil
- Ed Arce of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $10 on, Thursday, June 8th, 2023
